Addressing Gene-Edited Treg Manufacturing Bottlenecks From Early Development Through to Clinical Readiness

1:00 pm - Thursday 25th March 2027

  • Navigating donor-to-donor variability when developing manufacturing processes to improve consistency and support future scale-up initiatives
  • Optimizing analytical strategies and characterization approaches to ensure the right assays are in place for evaluating gene-edited Treg products throughout development
  • Balancing manufacturing scalability, product quality, and phenotypic functionality while preparing Treg therapies for successful clinical translation and broader commercialization

Speakers:

Chief Technology Officer
CoRegen